Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Bo Didley who wrote (1039)	10/8/1999 1:25:00 PM
From: Street Walker	Read Replies (1) \| Respond to of 5582

Nic Gum - article quitsmoking.about.com The idea of producing a Nic gum for 'maintance' is unique and may actually produce more revenue than the dosages needed for cessation. Think about it. Shorting the Common Cold and Nicotine Gum markets is a sure way of losing money. Whoever Gumm's joint venture partner will be, all we know is from Hans: a 150+ yr old international tobacco company with distribution to 140 countries and over 11,000 employees. Gary said at the shareholders meeting the "development in the works" will be announced this year. Tic Toc Tic Toc It would not suprise me at all to see other brokerage firms begin covering GUMM next year. I once put a professional short out of business. His friends sent a collection plate around to help him. Maybe we should look into investing in "collection plates" or coffin manufacturers<g>. What will GUMM come up with next? The FUNCTIONAL chewing gum market is an innovative means for drug delivery. Gary is the world specialist in gum formulation and it would not suprise me to see other 'joint ventures' to form in years to come with well recognized big pharma. A stock price in the hundreds would not suprise me in the least in years to come. Regards, S.W.